Tech Company Financing Transactions

Labrys Biologics Funding Round

Canaan Partners, InterWest Partners and Sofinnova Ventures joined a $31 million Series A capital raise for Labrys Biologics. The funding round was announced on 1/4/2013.

Transaction Overview

Company Information

Company Status

Acquired or Merged

Industry

Biopharmaceutical

Mailing Address

1700 Owens Street 595
San Francisco, CA 94158
USA

Phone

415-800-0800

Website

www.labrysbiologics.com

Email Address

Not Recorded

Overview

Labrys Biologics is a private, venture-financed development stage biotechnology company focused on treatments for chronic migraine. Labrys' lead candidate, RN-307, is an anti-CGRP monoclonal antibody for the treatment of chronic migraine slated to enter Phase 2 clinical trials in 2013.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Steven James

        

Chief Medical Officer

Marcelo Bigal

        

VP - Product Management

Michael Chang

        

VP - Regulatory Affairs

Michele Bronson

        

Browse more venture capital transactions:

Prev: 1/4/2013: Webvanta venture capital transaction
Next: 1/4/2013: Xtera Communications venture capital transaction

Share this article

About Our VC Transactions Data

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary